Clinical Trials Directory

Trials / Completed

CompletedNCT04495283

A Phase 2 Study to Evaluate Pregabalin and Acetaminophen Compared to Acetaminophen and Placebo in Subjects Undergoing Bunionectomy

A Phase 2, Randomized, Double-Blind, Placebo- and Comparator-Controlled Trial to Evaluate the Safety and Efficacy of Combination of Pregabalin and Acetaminophen Compared to Acetaminophen and Placebo in Subjects Undergoing Bunionectomy

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
87 (actual)
Sponsor
Nevakar, Inc. · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

A Phase 2, Randomized, Double-Blind, Placebo- and Comparator-Controlled Trial to Evaluate the Safety and Efficacy of Combination Pregabalin and Acetaminophen Compared to Acetaminophen and Placebo in Subjects Undergoing Bunionectomy

Detailed description

A Phase 2, Randomized, Double-Blind, Placebo- and Comparator-Controlled Trial to Evaluate the Safety and Efficacy of Combination Pregabalin and Acetaminophen Compared to Acetaminophen and Placebo in Subjects Undergoing Bunionectomy Up to 80 subjects will be randomized (32 in each active treatment group, 16 placebo). To evaluate the efficacy of combination pregabalin (PGB) and acetaminophen (APAP) administered vs. placebo for pain control in subjects undergoing bunionectomy. The placebo will be the saline solution.

Conditions

Interventions

TypeNameDescription
DRUGPregabalinPregabalin is a structural derivative of the inhibitory neurotransmitter gamma aminobutyric acid with anticonvulsant, anxiolytic and sleep-modulating properties.
DRUGAcetaminophenAcetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent.
OTHERPlacebo 1Placebo for APAP
OTHERPlacebo 2Placebo for combination

Timeline

Start date
2020-07-28
Primary completion
2020-11-12
Completion
2020-11-12
First posted
2020-07-31
Last updated
2021-11-23
Results posted
2021-11-23

Locations

2 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT04495283. Inclusion in this directory is not an endorsement.